The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

Autor: Markolf Hanefeld, Louise Traylor, Ling Gao, Wolfgang Landgraf

Publikováno v: Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-9 (2017)

Abstract Background Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and its impact on lipid an

Externí odkaz: https://doaj.org/article/0c83b953299b40d7923e5049c18f0db5

The Current and Potential Therapeutic Use of Metformin—The Good Old Drug

Autor: Józef Drzewoski, Markolf Hanefeld

Publikováno v: Pharmaceuticals, Vol 14, Iss 2, p 122 (2021)

Metformin, one of the oldest oral antidiabetic agents and still recommended by almost all current guidelines as the first-line treatment for type 2 diabetes mellitus (T2DM), has become the medication with steadily increasing potential therapeutic ind

Externí odkaz: https://doaj.org/article/c52177c55a0a42679fc2f61b89b5217e

Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers

Autor: Elena Henkel, Markolf Hanefeld, Stefan R. Bornstein, Bernhard Schipp, Jan Sradnick, Frank Pistrosch, Andreas L. Birkenfeld, Dorothea Schipp, Jan B. Matschke, Ingo Weigmann

Publikováno v: Diabetologia
Diabetologia, DOI: 10.1007/s00125-021-05562-9 (2021)

Aims/hypothesis Individuals with type 2 diabetes mellitus and subclinical inflammation have stimulated coagulation, activated platelets and endothelial dysfunction. Recent studies with the direct factor Xa inhibitor rivaroxaban in combination with lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cead87de1291ec3974235c7c0aa9e393
https://doi.org/10.1007/s00125-021-05562-9

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Autor: Matthew C. Riddle, Theodora Temelkova-Kurktschiev, Markolf Hanefeld, Wayne H-H Sheu, Ernesto Germán Cardona Muñoz, Hertzel C. Gerstein, Alvaro Avezum, William C. Cushman, Robert G. Hart, Rafael Diaz, Jan Basile, Nicolae Hancu, Helen M. Colhoun, Fady T. Botros, Fernando Lanas, Lars Rydén, Stephanie Hall, Patricio Lopez-Jaramillo, Lawrence A. Leiter, Petr Jansky, Jonathan E. Shaw, Matyas Keltai, Ignacio Conget, Mark Lakshmanan, Charles Atisso, Jeffrey L. Probstfield, Nana Pogosova, Peter J Raubenheimer, Leanne Dyal

Publikováno v: The Lancet Diabetes & Endocrinology. 8:106-114

Summary Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650198a64065c9515c8db9905df031e1
https://doi.org/10.1016/s2213-8587(19)30423-1

The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale

Autor: Zhiyong Zou, Dorota A. Zozulińska-Ziółkiewicz, Raffaele Izzo, Lena Tschiderer, Manuel F. Landecho, Kuo Liong Chien, Stefan Kiechl, Damiano Baldassarre, Matthias W. Lorenz, Tatjana Rundek, Mario Fritsch Neves, Jing Liu, Dirk Sander, Caroline Schmidt, Matthew Walters, Enrique Bernal, Gulay Asci, Rafael Gabriel, Michiel L. Bots, Bernhard Iglseder, Eric de Groot, Hirokazu Honda, Mark A. Espeland, Grace Parraga, Joline W.J. Beulens, Paolo Gresele, Pythia T. Nieuwkerk, Dianna Magliano, Michael J. Sweeting, Lars Lind, Kostas Kapellas, Tomi-Pekka Tuomainen, Maryam Kavousi, Frank P. Brouwers, Jean Philippe Empana, Markolf Hanefeld, Shuhei Okazaki, Menno V. Huisman, Jang Ho Bae, Daniel Staub, Aikaterini Papagianni, Gerhard Klingenschmid, Lisa Seekircher, Peter Willeit, Prabath W.B. Nanayakkara, Jackie F. Price, Johann Willeit, Radojica Stolić, Akihiko Kato, Alberico L. Catapano, Naveed Sattar, Christopher D. Byrne, Göran Bergström, Laura Calabresi, Robert Ekart, Michael H. Olsen, Michiaki Nagai, Michiel A. Van Agtmael, Marat Ezhov, Stefan Agewall, Eiichi Sato, Miles D. Witham, Eva Lonn

Publikováno v: Gerontology, 66(5), 447-459. KARGER
Gerontology, 66(5), 447-459. Karger
Gerontology, 66(5), 447-459. S. Karger AG
Tschiderer, L, Seekircher, L, Klingenschmid, G, Izzo, R, Baldassarre, D, Iglseder, B, Calabresi, L, Liu, J, Price, J F, Bae, J H, Brouwers, F P, de Groot, E, Schmidt, C, Bergström, G, Aşçi, G, Gresele, P, Okazaki, S, Kapellas, K, Landecho, M F, Sattar, N, Agewall, S, Zou, Z Y, Byrne, C D, Nanayakkara, P W B, Papagianni, A, Witham, M D, Bernal, E, Ekart, R, van Agtmael, M A, Neves, M F, Sato, E, Ezhov, M, Walters, M, Olsen, M H, Stolić, R, Zozulińska-Ziółkiewicz, D A, Hanefeld, M, Staub, D, Nagai, M, Nieuwkerk, P T, Huisman, M V, Kato, A, Honda, H, Parraga, G, Magliano, D, Gabriel, R, Rundek, T, Espeland, M A, Kiechl, S, Willeit, J & Proof-ATHERO Study Group 2020, ' The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium : Design and Rationale ', Gerontology, vol. 66, no. 5, pp. 447-459 . https://doi.org/10.1159/000508498
2020, ' The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale ', Gerontology, pp. 1-13 . https://doi.org/10.1159/000508498
Tschiderer, L, Seekircher, L, Klingenschmid, G, Izzo, R, Baldassarre, D, Iglseder, B, Calabresi, L, Liu, J, Price, J F, Bae, J H, Brouwers, F P, De Groot, E, Schmidt, C, Bergström, G, Aşçi, G, Gresele, P, Okazaki, S, Kapellas, K, Landecho, M F, Sattar, N, Agewall, S, Zou, Z Y, Byrne, C D, Nanayakkara, P W B, Papagianni, A, Witham, M D, Bernal, E, Ekart, R, Van Agtmael, M A, Neves, M F, Sato, E, Ezhov, M, Walters, M, Olsen, M H, Stolić, R, Zozulińska-Ziółkiewicz, D A, Hanefeld, M, Staub, D, Nagai, M, Nieuwkerk, P T, Huisman, M V, Kato, A, Honda, H, Parraga, G, Magliano, D, Gabriel, R, Rundek, T, Espeland, M A, Kiechl, S, Willeit, J, Lind, L, Empana, J P, Lonn, E, Tuomainen, T P, Catapano, A, Chien, K L, Sander, D, Kavousi, M, Beulens, J W J, Bots, M L, Sweeting, M J, Lorenz, M W & Willeit, P 2020, ' The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium : Design and Rationale ', Gerontology, vol. 66, no. 5, pp. 447-459 . https://doi.org/10.1159/000508498

Atherosclerosis - the pathophysiological mechanism shared by most cardiovascular diseases - can be directly or indirectly assessed by a variety of clinical tests including measurement of carotid intima-media thickness, carotid plaque, ankle-brachial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::973fc8e9ac93bb80b3c87a7280a096ad
https://doi.org/10.1159/000508498